Current News Releases 11/28/2018: ViaCyte, Inc. ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes. PHV 11.28.2018 | link 9/27/2018: ViaCyte, Inc. ViaCyte to Present at Investor, Partnering, and Scientific Conferences in October. PHV 9.27.2018 | link 9/25/2018: ViaCyte, Inc. Gore Strengthens Collaborative Relationship with ViaCyte by Investing Additional $10 Million. PHV 9.25.2018 | link Archived News Releases 8/21/2014: ViaCyte, Inc. ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC. PHV 8.21.2014 | link 8/19/2014: ViaCyte, Inc. ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of VC-01 Candidate Cell Replacement Therapy for Type 1 Diabetes. PHV 8.19.2014 | link 7/10/2013: ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes. PHV 7.10.2013 | link 2/13/2013: JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte. PHV 2.13.2013 | link 1/31/2013: ViaCyte's Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012. PHV 1.31.2013 | link 10/26/2012: ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy. PHV 10.26.2011 | link 8/22/2011: Wall Street Daily: This Biotech Discovery Causes HIV to Self-Destruct. PHV 8.22.2011 | link 8/17/2011: Fast Company: A New Plan To Mutate HIV Out Of Existence. PHV 8.17.2011 | link 7/20/2011: Forbes: Embracing the Enemy-Most HIV drugs work by halting the virus' reproduction. Biotech firm Koronis has a different idea. PHV 7.20.2011 | link 6/13/2011: Forbes: With Koronis, Is A Cure For HIV On The Horizon? PHV 6.13.2011 | link 5/31/2011: LA Times: ViaCyte progresses toward trials in stem cell diabetes treatment. PHV 5.31.2011 | link 3/21/2011: Daily Express: Koronis May Bring HIV Hope to Market. PHV 3.21.2011 | link 3/16/2011: Bioworld: Koronis Looking for Financing for HIV Viral Decay Accelerator. PHV 3.16.2011 | link 3/14/2011: Koronis Pharmaceuticals exploring alternatives for financing the late-stage development of KP-1461 against HIV. PHV 3.14.2011 | link 2/22/2011: Genetic Engineering News Podcast with Mark Fromhold, Ph.D., Koronis Pharmaceuticals. The significance of the KP-1461 clinical trial findings. PHV 2.22.2011 | link 1/26/2011: Wedbush Securities: The Potential Disruptive Effect that Koronis Pharmaceuticals Could Have on the Existing HIV Market PHV 1.26.2011 | link 1/19/2011: Koronis Pharmaceuticals - Clinical Trial Results Demonstrate Promise for First Non-suppressive HIV Drug PHV 1.17.2011 | link 9/9/2010: Koronis Pharmaceuticals Announces Late-Breaker Oral Presentation on HIV Therapeutic Candidate KP-1461 at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) PHV 9.23.2010 | link 9/1/2010: 2010 & Beyond: A look at forthcoming new HIV meds and novel ways that treatment could advance over the coming decade. PHV 9.23.2010 | link 4/29/2010: Koronis Pharmaceuticals to Present at 2010 BIO International Convention PHV 4.29.2010 | link 10/28/2009: Novocell is the Recipient of a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes PHV 10.30.2009 | link 7/31/2009: Need for Novel Approaches to Treating HIV Still Exists (Koronis) PHV 7.31.2009 | link 5/19/2009: Koronis Pharmaceuticals' Scientific Advisory Board Confirms KP-1461 Clinical Drug Activity, HIV Ablation PHV 5.19.2009 | link 05/11/2009: Novocell Names John West Chief Executive Officer PHV 5.14.2009 | link 05/06/2009: Novocell Receives Grant Awards from California Institute for Regenerative Medicine for Stem Cell Therapy Development PHV 5.14.2009 | link 2/09/2009: HIV Mutates to Death With New Drug PHV 2.10.2009 | link 12/22/2008: TransMolecular Receives Orphan Drug Designation for 131I-TM601 PHV 2.9.2009 | link 12/19/2008: Novocell Announces Non-Exclusive Drug Discovery Collaboration with Pfizer PHV 2.9.2009 | link 12/9/2008: Novocell Announces Collaboration with World-Renowned Stem Cell Researcher PHV 2.9.2009 | link 11/25/2008: Novocell CEO to Head Juvenile Diabetes Research Foundation (JDRF) PHV 2.9.2009 | link 9/30/2008: Koronis Pharmaceuticals Announces Appointment of Prominent HIV Researcher Courtney Fletcher, Pharm. D., to Scientific Advisory Board and Jeff Parkins as VP, Clinical Development PHV 10.28.2008 | link 9/29/2008: Dosing Initiated in TransMolecular's Phase 1/2 Clinical Trial PHV 11.5.2008 | link 9/17/2008: Novocell Awarded Landmark U.S. Patents for Innovative Stem Cell Technologies PHV 10.27.2008 | link 6/15/2008: Today's biopharma venture capital challenge: Risk-sharing models versus risk avoidance PHV 7.1.2008 | link 6/9/2008: Novocell's Emmanuel Baetge, Ph.D., Featured in Forbes cover story: "Stem Cells Get Real" PHV 7.1.2008 | link 12/27/2007: Pacific Horizon Could Reap Illumigen Sale Windfall PHV 1.5.2008 | link 12/26/2007: Cubist Pharmaceuticals Acquires Illumigen Biosciences PHV 12.27.2007 | link 10/17/2007: Seattle Times-Cubist gets option to acquire Illumigen PHV 10.17.2007 | link 10/16/2007: Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen Biosciences PHV 10.16.2007 | link 9/25/2007: New Kind of Antiretroviral, KP-1461; Clinical Trial Recruiting. Interview with Stephen Becker, M.D. PHV 9.25.2007 | link 8/10/2007: Fierce Biotech-Emerging Drug Developers: Koronis Pharmaceuticals PHV 9.25.2007 | link 7/16/2007: Novocell Raises $25 Million PHV 7.25.2007 | link 6/28/2007: Koronis Pharmaceuticals Raises $20 Million PHV 7.3.2007 | link 6/26/2007: Koronis Pharmaceuticals Begins Phase 2a Proof of Concept Study of KP-1461 PHV 7.3.2007 | link Return to top of page ^ © Pacific Horizon Ventures.